Furthermore, recent clinical evidence has identified AD-specific phosphoepitopes of tau Janelidze et al. (2020); Palmqvist et al. (2020); Thijssen et al. (2020), suggesting that amyloid comorbidity in AD may influence the ways in which tau is posttranslationally modified, which in turn leads to distinct patterns of neurodegeneration relative to primary tauopathies. The gene discussed is MAPT; the disease is tauopathy.